Jeff Sorenson and Gael Kuhn, Co-founders, Yunu, speak on what they think the future looks like when it comes to streamlining and improving the clinical trial imaging landscape.
ACT: Looking towards the future, what role do you see Yunu playing in further streamlining and improving the clinical trial imaging landscape, and how is your technology evolving to address emerging challenges?
Sorenson: Yunu uniquely provides a real time imaging data repository that's constantly being updated and enriched for its clients. We're driving both prospective and retrospective image analysis simultaneously.
Kuhn: Yunu already helps extract information from the imaging data of the assessment platform using both manual and automated measurements. We are now developing a data analytics platform that will allow investigators and trial sponsors to extract knowledge from this information. Real time access to live data and try wide analytics platforms will allow rapid testing of new InSilico hypothesis. Finally, Yunu has developed an algorithm platform allowing outside innovation to be integrated within the inflight clinical trial.
Sorenson: Yunu sees a future where imaging clinical trials are set up by the sponsor and other stakeholders, and they can invite others into the workflows. They can be in control system and everyone downstream who's using it. Pristine prospective data capture and accurate real time measurements from the field are top priorities in the near term, we have to make sure that we're capturing all of the pristine, prospective data in clinical trials. Once we start doing that, you can then have the inclusion of inflight radiomics. You can create things out of the data, improve your trial, and apply innovative biomarkers in the active clinical trials. So, the data can help create radiomics that then can help create additional data and improve these trials. This is ultimately how imaging can be brought more closely into tomorrow's precision medicine.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.
SCOPE Summit 2025: Enhancing the Patient Experience Through Site Centricity
February 12th 2025In an interview with ACT senior editor Andy Studna at SCOPE Summit, Ashley Davidson, vice president, product lead - sponsor tech strategy, Advarra, highlights the need for more site-centric approaches in study startup.